Literature DB >> 670391

Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.

J Over, J J Sixma, M H Bruïne, M C Trieschnigg, R A Vlooswijk, N H Beeser-Visser, B N Bouma.   

Abstract

Radiolabeled human Factor VIII was used to study its survival in normals and patients with classic hemophilia, and to study the heterogeneity of Factor VIII; Purified Factor VIII was radiolabeled with 125iodine (125I-VIII) without loss of its structural integrity. The survival of 125I-VIII was studied in six normals and six hemophiliacs of whom four of the hemophiliacs had received transfusions with normal cryoprecipitate before the 125I-VIII infusion. No significant difference was observed between the disappearance of Factor VIII coagulant activity and radioactivity in these hemophiliacs. 125I-VIII in plasma showed a biphasic disappearance with an average t1/2 of 2.9 +/- 0.4 h (SEM) for the first phase and 18.6 +/- 0.7 h (SEM) for the second phase, respectively. The survival of 125I-VIII was similar comparing normals and hemophiliacs. The highest molecular weight forms of Factor VIII disappear more rapidly than the lower molecular weight ones. This was established by analysis of the fractions obtained by gel chromatography of plasma collected at several times after infusion and by analysis of the in vivo disappearance of three subfractions of Factor VIII. The fraction of 125I-VIII binding to platelets in the presence of ristocetin (containing the highest molecular weight forms of Factor VIII including the ristocetin cofactor) represented about 50% of the radioactivity present in plasma after infusion and showed a t 1/2 of 11.7 +/- 0.9 h (SEM) for the second phase. The fraction, which was recovered in cryoprecipitate of the recipient's plasma, represented about 90% of the initial radioactivity and showed a t 1/2 of 16.3 +/- 0.8 h (SEM) for the second phase. The fraction of 125I-VIII remaining in the cryosupernatant plasma (containing low molecular weight forms of Factor (VIII) showed a t 1/2 of 27.2 +/- 1.1 h (SEM). The first phase of the disappearance of 125I-VIII is caused in part by the disappearance of the highest molecular weight forms, which are possibly removed by the reticuloendothelial system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 670391      PMCID: PMC371757          DOI: 10.1172/JCI109120

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  THE FATE OF PROTHROMBIN AND FACTORS VIII, IX AND X TRANSFUSED TO PATIENTS DEFICIENT IN THESE FACTORS.

Authors:  R BIGGS; K W DENSON
Journal:  Br J Haematol       Date:  1963-10       Impact factor: 6.998

2.  Observations on plasma banking and transfusion procedures for haemophilic patients using a quantitative assay for antihaemophilic globulin (AHG).

Authors:  J G POOL; J ROBINSON
Journal:  Br J Haematol       Date:  1959-01       Impact factor: 6.998

3.  HEMOPHILIA. I. THE ABNORMAL COAGULATION OF THE BLOOD AND ITS RELATION TO THE BLOOD PLATELETS.

Authors:  A J Patek; R P Stetson
Journal:  J Clin Invest       Date:  1936-09       Impact factor: 14.808

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Assay of f. VIII-related antigen in a variant of von Willebrand's disease.

Authors:  J Over; H A Vlooswijk; J J Sixma
Journal:  Thromb Haemost       Date:  1977-04-30       Impact factor: 5.249

6.  Macromolecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion.

Authors:  T R Griggs; J S Potter; S B McClanahan; W P Webster; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

7.  Studies on the prolonged bleeding time in von Willebrand's disease.

Authors:  P M Mannucci; F I Pareti; L Holmberg; I M Nilsson; Z M Ruggeri
Journal:  J Lab Clin Med       Date:  1976-10

8.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

9.  Infusion of human and canine factor VIII in dogs with von Willebrand's disease: studies of the von Willebrand and factor VIII synthesis stimulating factors.

Authors:  B N Bouma; W J Dodds; J A van Mourik; J J Sixma; W P Webster
Journal:  Scand J Haematol       Date:  1976-10

10.  Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate.

Authors:  J Over; B N Bouma; J A van Mourik; J J Sixma; R Vlooswijk; I Bakker-Woudenberg
Journal:  J Lab Clin Med       Date:  1978-01
View more
  17 in total

Review 1.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

2.  Structural analysis of factor VIII antigen in von Willebrand disease.

Authors:  R L Nachman; E A Jaffe; C Miller; W T Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

3.  Von Willebrand's disease: a clinical and molecular enigma. Twelfth Annual Paul M. Aggeler Memorial Lecture.

Authors:  R L Nachman
Journal:  West J Med       Date:  1982-04

Review 4.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

6.  Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2014-01-02       Impact factor: 1.627

7.  Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.

Authors:  E A Tuley; C Gaucher; S Jorieux; N K Worrall; J E Sadler; C Mazurier
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

8.  Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells.

Authors:  R J Kaufman; L C Wasley; M V Davies; R J Wise; D I Israel; A J Dorner
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

9.  Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen.

Authors:  J J Sixma; K S Sakariassen; H V Stel; W P Houdijk; D W In der Maur; R J Hamer; P G de Groot; J A van Mourik
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

10.  Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.

Authors:  S Björkman; M Carlsson; E Berntorp; P Stenberg
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.